Skip to main content
OpenTrials
Completed

NCT Number: NCT01563679

Analysis of Percutaneous Ablations for Cancer Treatment

This is a study involving patients with cancer who are referred by their treating physician for percutaneous locoregional therapies.

Patient's clinical and radiology findings, pathology findings, survival, treatment responses, and complications after their locoregional therapy will be studied.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cancer Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Emory University Hospital

Altanta, Georgia, 30322, United States

About this study

The efficacy of the percutaneous and transarterial treatments for solid tumors will be studied. Prospective study on patients who receive percutaneous locoregional therapies, including radiofrequency ablation (RFA), cryoablation, microwave ablation, IRE and chemical ablation for treatment of cancer will be performed.

Preoperative clinic chart, procedure note, postoperative chart, pre- and post-operative CT, MRI or Ultrasound, angiographic findings, biopsy results and pathologic findings, will be reviewed. Patient survival, treatment responses, complications after the therapy will be collected from clinic visits and clinical encounters.

Patient overall performance status before and after procedures will be assessed using the Quality of Life questionnaire (SF-36™ Health Survey).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18yrs of age
  • Cancer diagnosis
  • Candidate for Locoregional therapy
  • Willingness to sign informed consent

Exclusion criteria

  • Unable to sign informed consent
  • Patients not eligible for locoregional therapies

Treatment and study plan

Primary outcomes

  1. Effect of percutaneous and transarterial treatments for cancer in quality of life

    Time frame: 1 year

    Patients will complete the QOL questionnare during their follow up visits after procedure. 1 month, 3 months, 6 months and 1 year.

Secondary outcomes

  1. response rate to percutaneous and transarterial treatment for cancer

    Time frame: 1 month, 3 months, 6 months, 1 year.

    Patients will be followed up 1, 3, 6 and 1year intervals after procedure.

Sponsors and collaborators

Lead sponsor

Emory University

Other

Registry information

Official study title

Prospective Analysis of Percutaneous Ablations for Cancer Treatment

Important dates

Study start
2012
Primary completion
2014
Study completion
2014
First posted
Mar 27, 2012
Registry last updated
May 28, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.